http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022098850-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d041d858232e98914bd54787ef98e0e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_569fdf83f33f3840611c32e2ae639c04 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2021-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_973089fb2b855100c255736bfeddb4df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1f922e5af071f8de0f3f83c286a2be4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9e1a763f23366c861ae4affc6675622 |
| publicationDate | 2022-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022098850-A1 |
| titleOfInvention | Engineered t cell receptors targeting egfr antigens and methods of use |
| abstract | This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize EGFR neoantigens comprising L858R mutations and restricted to HLA class I A11 allotype. Accordingly, aspects of the disclosure relate to a polypeptide comprising an antigen binding variable region comprising the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure. Further aspects relate to an engineered T-cell Receptor (TCR) comprising a TCR-b polypeptide and a TCR-a polypeptide, wherein the TCR-b polypeptide comprises an amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure and the TCR-a polypeptide comprises the amino acid sequence of a CDR3 of the disclosure or an amino acid sequence with at least 80% sequence identity to a CDR3 of the disclosure. |
| priorityDate | 2020-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 234.